
Diagnostics

Key launches 2017: All targets achieved

	Area	Product	Market
Instruments/ Devices	Central Laboratory	cobas 8000 <e 801 > - High throughput immunochemistry analyser	US ✓
		CCM High Speed - cobas connection module (CCM) for up to 6000 samples/hour	WW ✓
	Coagulation Testing	cobas t 511 / t 711 - Medium and high volume coagulation systems	EU ✓
	Point of Care	CoaguChek Vantus - Hand-held coagulation monitoring system for Patient Self-Testing	US ✓
	Diabetes Care	Accu-Chek Instant bG System - Effortless, accurate and affordable bG system for price sensitive markets	EU ✓
Tests/ Assays	HPV	cobas HPV - Next generation HPV DNA test leveraging 68/8800 Automation to detect 14 hrHPV with simultaneous detection of genotypes 16 and 18	EU ✓
		CINtec Histology - Diagnostic component of the Roche Cervical Cancer portfolio	US ✓
	Virology	cobas HIV 1&2 Qual - For use on the cobas 6800/8800 Systems; for diagnosis of acute HIV 1 or 2 infection and for confirmation of HIV 1 or 2 infection	EU ✓
	Sequencing	AVENIO ctDNA panels - Liquid biopsy for circulating tumor DNA, 3 panels: targeted panel (17 genes for cancer therapy selection), expanded panel (77 genes for cancer therapy selection), surveillance panel (197 genes)	EU/US ✓
	cobas Liat	cobas Liat C.diff - Qualitative IVD test, that utilizes real-time PCR, for the direct detection of the tcdB gene of toxigenic <i>C. difficile</i> in unformed stool specimens	EU ✓
		cobas Liat MRSA/SA - Qualitative IVD test, that utilizes real-time PCR, for the direct detection of MRSA and <i>Staphylococcus aureus</i> DNA from nasal swabs	EU ✓
	Women's Health	AMH - Immunoassay for the in vitro quantitative determination of anti-Mullerian hormone (AMH) in human serum and plasma for the assessment of the ovarian reserve in women presenting to fertility clinics	US ✓
Companion Diagnostics	PD-L1 (SP142) for Bladder Cancer* - complementary diagnostic for Tecentriq	EU ✓	
	PD-L1 (SP142) for NSCLC* - complementary diagnostic for Tecentriq	EU ✓	

* = Achieve commercial readiness, dependent on Pharma label and approval

Doing now what patients need next